Vident Advisory LLC Purchases Shares of 12,377 Genmab A/S Sponsored ADR $GMAB

Key Points

• Vident Advisory LLC has acquired 12,377 shares of Genmab A/S, valued at approximately $242,000, highlighting growing interest from institutional investors in the company.
• Recent analyst reports show a mixed outlook for Genmab A/S, with price target increases from Truist Financial and HC Wainwright, while Zacks downgraded the stock from "strong-buy" to "hold."
• Genmab A/S reported $0.54 EPS for the last quarter, exceeding expectations, and has a current market capitalization of $17.86 billion.

Vident Advisory LLC purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 12,377 shares of the company's stock, valued at approximately $242,000.

Other large investors have also added to or reduced their stakes in the company. Headlands Technologies LLC grew its stake in Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after purchasing an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after purchasing an additional 1,070 shares during the last quarter. Barclays PLC grew its stake in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Genmab A/S during the 4th quarter valued at about $60,000. Finally, Brooklyn Investment Group grew its stake in Genmab A/S by 729.3% during the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock valued at $83,000 after purchasing an additional 3,734 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Wall Street Analyst Weigh In

GMAB has been the topic of several research analyst reports. Truist Financial boosted their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. HC Wainwright upped their target price on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Finally, Zacks Research downgraded Genmab A/S from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $37.60.

Genmab A/S Trading Up 1.1%

Shares of GMAB stock opened at $27.83 on Wednesday. The company has a market capitalization of $17.86 billion, a P/E ratio of 13.98, a P/E/G ratio of 1.61 and a beta of 0.93. The business's 50 day moving average is $23.10 and its two-hundred day moving average is $21.53. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $27.87.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, research analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.